Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

1 In this article, we explore the impact of incretin-mimetic drugs on muscle health and what can be done to limit these severe side effects. Incretins are intestinal hormones secreted in response to ...

Eli Lilly LLY2.29%increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...